ResultsIQ › Latest results › Entero Healthcare Solutions Limited
Entero Healthcare Solutions Limited Q2 FY27 results deck summary
NSE: ENTERO · BSE: 544122
Results deck of 4 Nov 2026, summarised by AI from the filing.
Q2FY27 revenue ₹2,087.1 cr (+33% YoY) with EBITDA margin at 5.3%; management is on track against full year guidance.
Key takeaways
- FY27 guidance Management is on track to deliver comfortably against full year guidance; FY27 MedTech revenue is expected to cross ₹1,000 cr.
- Organic growth Organic revenue growth of 18.2% in Q2FY27 was 1.3x IPM growth, with no new acquisitions in the quarter.
- Receivable timing Operating cashflow was negative on timing of trade receivables on certain government contracts, with collection received in November.
Entero Healthcare Solutions Limited Q2 FY27 results
As filed: Revenue ₹2,087 cr (+33% year on year), EBITDA ₹111 cr (+79% year on year), PAT ₹60.7 cr (+64% year on year), EBITDA margin 5.3% (+136 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹1,941 cr (+38% year on year), EBITDA ₹97.0 cr (+94% year on year), PAT ₹52.1 cr (+74% year on year), EBITDA margin 5.0% (+144 bps). Score 78 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 144 bps year on year. Consolidated profit +73% but standalone -51%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹537 cr on a year ago, more than the ₹307 cr it added the year before. Share price after the results: +47.1% in 28 days (Nifty 500: −1.9%).
- Q4 FY26: Revenue ₹1,910 cr (+43% year on year), EBITDA ₹86.0 cr (+79% year on year), PAT ₹45.1 cr (+46% year on year), EBITDA margin 4.5% (+92 bps). Score 85 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 92 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹14.1 cr on a year ago, more than the ₹10.0 cr it added the year before. Share price after the results: −13.8% in 30 days (Nifty 500: +0.9%).
- Q3 FY26: Revenue ₹1,707 cr (+26% year on year), EBITDA ₹67.8 cr (+38% year on year), PAT ₹33.9 cr (+25% year on year), EBITDA margin 4.0% (+37 bps). Score 36 of 100, Below trend. Revenue and profit before exceptional items growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 37 bps year on year. Consolidated profit +17% but standalone -93%. Revenue rose ₹348 cr on a year ago, against ₹366 cr the year before. Share price after the results: −12.4% in 29 days (Nifty 500: −9.6%).
- Q2 FY26: Revenue ₹1,571 cr (+21% year on year), EBITDA ₹62.0 cr (+48% year on year), PAT ₹37.0 cr (+42% year on year), EBITDA margin 4.0% (+72 bps). Score 73 of 100, Above trend. EBITDA margin rose 72 bps year on year. Consolidated profit +42% but standalone -60%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −12.2% in 30 days (Nifty 500: −0.5%).
- Q1 FY26: Revenue ₹1,404 cr (+28% year on year), EBITDA ₹50.0 cr (+61% year on year), PAT ₹30.0 cr (+43% year on year), EBITDA margin 3.6% (+74 bps). Score 80 of 100, Above trend. EBITDA margin rose 74 bps year on year. Consolidated profit +43% but standalone -67%. Not enough history for a trend yet: scored on growth alone. Profit fell 3% from last quarter. Share price after the results: −6.6% in 28 days (Nifty 500: +1.7%).
- Q4 FY25: Revenue ₹1,339 cr (+30% year on year), EBITDA ₹48.0 cr (+66% year on year), PAT ₹31.0 cr (+48% year on year), EBITDA margin 3.6% (+78 bps). Score 82 of 100, Above trend. EBITDA margin rose 78 bps year on year. Consolidated profit +48% but standalone -173%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −23.5% in 30 days (Nifty 500: +3.1%).
- Q3 FY25: Revenue ₹1,359 cr (+37% year on year), EBITDA ₹49.0 cr (+75% year on year), PAT ₹29.0 cr (+300% year on year), EBITDA margin 3.6% (+79 bps). Score 91 of 100, Above trend. EBITDA margin rose 79 bps year on year. Not enough history for a trend yet: scored on growth alone.
Past price moves after results do not indicate future moves. Not a recommendation.
Entero Healthcare Solutions Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (5 Nov 2026), Results deck (4 Nov 2026)
- Q1 FY27: Earnings call (10 Aug 2026), Results deck (7 Aug 2026)
- Q4 FY26: Earnings call (26 May 2026), Results deck (25 May 2026)
- Q3 FY26: Earnings call (13 Feb 2026), Results deck (12 Feb 2026)
- Q2 FY26: Earnings call (13 Nov 2025), Results deck (12 Nov 2025)
- Q1 FY26: Earnings call (11 Aug 2025), Results deck (8 Aug 2025)
- Q4 FY25: Earnings call (28 May 2025), Results deck (27 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.